Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other financing activities (2024 - 2025)

Historic Other financing activities for Allogene Therapeutics (ALLO) over the last 2 years, with Q2 2025 value amounting to $3.6 million.

  • Allogene Therapeutics' Other financing activities rose 5605.26% to $3.6 million in Q2 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 20298.25%. This contributed to the annual value of $2.3 million for FY2024, which is N/A changed from last year.
  • Allogene Therapeutics' Other financing activities amounted to $3.6 million in Q2 2025, which was up 5605.26% from $3.4 million recorded in Q1 2025.
  • Allogene Therapeutics' 5-year Other financing activities high stood at $3.6 million for Q2 2025, and its period low was $2.3 million during Q2 2024.